RE: SDC-1801 clinical trial completed successfully15 Aug 2024 07:37
If we take JP Morgan's figure of $47 Million - $55 Million average for a pre-clinical licencing deal in 2023 that bodes very well for Sareum's SDC1801.
If, however, we move to P2 with a partnership the sums involved are even greater, in the hundreds of millions ($300 million being the average price paid in 2023 for P2, according to JP Morgan). i.e. The big opportunity for Sareum now that we are a P1 clinical company is that most license deals with big pharma happen at platform and discovery stages. It's well worth checking out the Akeso deal, as an example. They were paid $500 million upfront by Summit Therapeutics in 2023 to in-license ivonescimab. Additionally, the partnership outlines a potential deal value of up to USD 4.5 billion.
Then there's the Alnylam deal last year. They received an upfront cash payment of USD 310 million from Roche to co-develop and co-commercialize Zilebesiran. Additional development, regulatory, and sales milestones could potentially elevate the deal value to USD 2.8 billion.
Also in 2023, Evotec was paid $50 Million upfront by Bristol Myers Squibb. Tiered royalties on product sales further underscore the financial commitment, resulting in USD 4bn potential deal value.
Plus in 2023 Kelun-Biotech was paid an upfront sum of $175 Million by Merck to co-develop preclinical antibody-drug conjugates. Future development, regulatory, and sales milestone payments, which could total up to USD 9.3 billion.
That's why many of us are invested in Sareum for the (very) long haul because if we get a similar deal the SAR share price will be in the pounds not the pence....
Good luck, Brighty
Sign In
Follow the stocks
